SARS-CoV-2 B.1.617 Mutations L452R and E484Q Are Not Synergistic for Antibody Evasion-Reference-Cited by-同舟云学术

SARS-CoV-2 B.1.617 Mutations L452R and E484Q Are Not Synergistic for Antibody Evasion

Published:2021-09-09 Issue:6 Volume:224 Page:989-994
ISSN:0022-1899
Container-title:The Journal of Infectious Diseases
language:en
Short-container-title:

Author:

Ferreira Isabella A T M¹²,Kemp Steven A¹²,Datir Rawlings¹²,Saito Akatsuki³,Meng Bo¹²,Rakshit Partha⁴,Takaori-Kondo Akifumi⁵,Kosugi Yusuke⁶,Uriu Keiya⁶,Kimura Izumi⁶,Shirakawa Kotaro⁵,Abdullahi Adam¹²,Agarwal Anurag⁷,Ozono Seiya⁸,Tokunaga Kenzo⁸,Sato Kei⁶⁹^ORCID,Gupta Ravindra K¹²¹⁰^ORCID, ,

Affiliation:

1. Cambridge Institute of Therapeutic Immunology and Infectious Disease, Cambridge,United Kingdom

2. Department of Medicine, University of Cambridge, Cambridge,United Kingdom

3. Department of Veterinary Medicine, Faculty of Agriculture, University of Miyazaki, Miyazaki,Japan

4. National Centre for Disease Control, Delhi,India

5. Department of Hematology and Oncology, Kyoto University, Kyoto,Japan

6. Division of Systems Virology, Institute of Medical Science, University of Tokyo, Tokyo, Japan

7. CSIR Institute of Genomics and Integrative Biology, Delhi,India

8. Department of Pathology, National Institute of Infectious Diseases, Tokyo,Japan

9. CREST , Japan Science and Technology Agency, Saitama,Japan

10. Africa Health Research Institute, Durban,South Africa

Abstract

Abstract The SARS-CoV-2 B.1.617 variant emerged in the Indian state of Maharashtra in late 2020. There have been fears that 2 key mutations seen in the receptor-binding domain, L452R and E484Q, would have additive effects on evasion of neutralizing antibodies. We report that spike bearing L452R and E484Q confers modestly reduced sensitivity to BNT162b2 mRNA vaccine-elicited antibodies following either first or second dose. The effect is similar in magnitude to the loss of sensitivity conferred by L452R or E484Q alone. These data demonstrate reduced sensitivity to vaccine-elicited neutralizing antibodies by L452R and E484Q but lack of synergistic loss of sensitivity.

Funder

Wellcome Trust

AMED

COVID-19 Genomics UK

Medical Research Council UK Research and Innovation

National Institute of Health Research

Genome Research Ltd

Cambridge NIHRB

Biomedical Research Centre

Bill and Melinda Gates Foundation

Rosetrees Trust

Publisher

Oxford University Press (OUP)

Subject

Infectious Diseases,Immunology and Allergy

Link

http://academic.oup.com/jid/advance-article-pdf/doi/10.1093/infdis/jiab368/38982145/jiab368.pdf

Reference15 articles.

1. SARS-CoV-2 evolution during treatment of chronic infection;Kemp;Nature,2021

2. Complete Mapping of Mutations to the SARS-CoV-2 Spike Receptor-Binding Domain that Escape Antibody Recognition;Greaney;Cell host & microbe,2020

3. SARS-CoV-2 immune evasion by the B. 1.427/B. 1.429 variant of concern;McCallum;Science,2021

4. Transmission, infectivity, and antibody neutralization of an emerging SARS-CoV-2 variant in California carrying a L452R spike protein mutation;Deng,2021

5. An emerging SARS-CoV-2 mutant evading cellular immunity and increasing viral infectivity;Motozono,2021

Cited by 144 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. A highly sensitive on-site duplex genotyping method dRPG for simultaneous detection of SARS-CoV‑2 key mutations with single nucleotide resolution;Sensors and Actuators B: Chemical;2024-11

2. Virological characteristics of the SARS‐CoV‐2 Omicron EG.5.1 variant;Microbiology and Immunology;2024-07-04

3. SARS-CoV-2 Delta variant remains viable in environmental biofilms found in meat packaging plants;PLOS ONE;2024-06-13

4. Differential responses of SARS-CoV-2 variants to environmental drivers during their selective sweeps;Scientific Reports;2024-06-10

5. Virological characteristics of a SARS-CoV-2-related bat coronavirus, BANAL-20-236;eBioMedicine;2024-06